ViewRay, Inc. (VRAY): Price and Financial Metrics


ViewRay, Inc. (VRAY): $4.52

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VRAY POWR Grades

  • Growth is the dimension where VRAY ranks best; there it ranks ahead of 56.64% of US stocks.
  • VRAY's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • VRAY ranks lowest in Quality; there it ranks in the 11th percentile.

VRAY Stock Summary

  • VRAY's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 269.38 -- higher than 90.18% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 9.33, VIEWRAY INC has a higher such ratio than 86.89% of stocks in our set.
  • VIEWRAY INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -10.05%, greater than the shareholder yield of 26.16% of stocks in our set.
  • Stocks that are quantitatively similar to VRAY, based on their financial statements, market capitalization, and price volatility, are VHC, SMRT, WRAP, MKFG, and MXCT.
  • VRAY's SEC filings can be seen here. And to visit VIEWRAY INC's official web site, go to www.viewray.com.

VRAY Valuation Summary

  • In comparison to the median Healthcare stock, VRAY's price/earnings ratio is 133.94% lower, now standing at -7.5.
  • VRAY's price/earnings ratio has moved down 3.9 over the prior 83 months.

Below are key valuation metrics over time for VRAY.

Stock Date P/S P/B P/E EV/EBIT
VRAY 2023-01-30 9.1 7.7 -7.5 -7.0
VRAY 2023-01-27 9.3 7.9 -7.7 -7.2
VRAY 2023-01-26 9.3 7.9 -7.7 -7.2
VRAY 2023-01-25 9.6 8.1 -7.9 -7.4
VRAY 2023-01-24 9.9 8.4 -8.2 -7.7
VRAY 2023-01-23 9.8 8.3 -8.1 -7.6

VRAY Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 280.75%.
  • The 3 year price growth rate now stands at -65.58%.
  • Its 4 year revenue growth rate is now at 353.95%.
VRAY's revenue has moved up $120,000 over the prior 33 months.

The table below shows VRAY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 87.902 -74.412 -106.582
2022-06-30 80.589 -76.112 -105.736
2022-03-31 73.47 -68.169 -109.079
2021-12-31 70.119 -62.091 -110.048
2021-09-30 68.189 -60.183 -109.079
2021-06-30 59.098 -58.768 -111.943

VRAY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRAY has a Quality Grade of F, ranking ahead of 4.3% of graded US stocks.
  • VRAY's asset turnover comes in at 0.212 -- ranking 141st of 186 Medical Equipment stocks.
  • DXCM, SRTS, and SMTI are the stocks whose asset turnover ratios are most correlated with VRAY.

The table below shows VRAY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 -0.038 -0.931
2021-03-31 0.204 -0.028 -0.887
2020-12-31 0.194 -0.071 -0.869
2020-09-30 0.174 -0.148 -0.903
2020-06-30 0.218 -0.099 -0.769
2020-03-31 0.278 -0.027 -0.752

VRAY Price Target

For more insight on analysts targets of VRAY, see our VRAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.88 Average Broker Recommendation 1.29 (Strong Buy)

VRAY Stock Price Chart Interactive Chart >

Price chart for VRAY

VRAY Price/Volume Stats

Current price $4.52 52-week high $4.96
Prev. close $4.52 52-week low $2.39
Day low $4.45 Volume 568,700
Day high $4.57 Avg. volume 1,049,880
50-day MA $4.59 Dividend yield N/A
200-day MA $3.70 Market Cap 820.00M

ViewRay, Inc. (VRAY) Company Bio


ViewRay, Inc. designs, manufactures, and markets radiation therapy systems worldwide. It offers MRIdian, a MRI-guided radiation therapy system that images and treats cancer patients simultaneously. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. The company markets its MRIdian through a direct sales force in the United States and distributors worldwide to a range of customers, including university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. was founded in 2004 and is based in Oakwood Village, Ohio.


VRAY Latest News Stream


Event/Time News Detail
Loading, please wait...

VRAY Latest Social Stream


Loading social stream, please wait...

View Full VRAY Social Stream

Latest VRAY News From Around the Web

Below are the latest news stories about VIEWRAY INC that investors may wish to consider to help them evaluate VRAY as an investment opportunity.

ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023

ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results.

Yahoo | January 31, 2023

Amarin and ViewRay Stock See Action From Activist Investors

Sarissa Capital is pushing to get a slate of directors on the board of pharmaceutical firm Amarin. Hudson Executive disclosed a large stake in radiation-treatment equipment maker ViewRay.

Yahoo | January 27, 2023

ViewRay Enters into Cooperation Agreement with Hudson Executive Capital

ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors (the "Board"), effective as of January 20, 2023.

Yahoo | January 20, 2023

Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. (NASDAQ: VRAY) today announced that findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy – delivered with MRIdian – to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also asso

Yahoo | January 12, 2023

ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change.

Yahoo | January 9, 2023

Read More 'VRAY' Stories Here

VRAY Price Returns

1-mo -1.95%
3-mo 0.00%
6-mo 21.83%
1-year 3.43%
3-year 51.68%
5-year -42.64%
YTD 0.89%
2022 -18.69%
2021 44.24%
2020 -9.48%
2019 -30.48%
2018 -34.45%

Continue Researching VRAY

Here are a few links from around the web to help you further your research on ViewRay Inc's stock as an investment opportunity:

ViewRay Inc (VRAY) Stock Price | Nasdaq
ViewRay Inc (VRAY) Stock Quote, History and News - Yahoo Finance
ViewRay Inc (VRAY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8515 seconds.